| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A CDC7-selective Inhibitor, TAK-931, suppresses homologous recombination repair activity to enhance antiproliferative activity of a PARP inhibitor
|
Yu, J.
|
|
|
138 |
S2 |
p. S36
|
artikel
|
| 2 |
A comprehensive analysis of cetuximab combinatorial polymeric nanocomplexes with potent radionuclide uptake to combat metastatic liver cancer
|
Poojari, R.
|
|
|
138 |
S2 |
p. S38
|
artikel
|
| 3 |
Acquired resistance to selective FGFR inhibitors in FGFR-altered cholangiocarcinoma
|
Goyal, L.
|
|
|
138 |
S2 |
p. S21-S22
|
artikel
|
| 4 |
A FliC armed oncolytic tanapoxvirus causes regression of colorectal cancer xenografts in immuno-competent models
|
Kana, S.I.
|
|
|
138 |
S2 |
p. S58
|
artikel
|
| 5 |
A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model
|
Ciccone, D.
|
|
|
138 |
S2 |
p. S20
|
artikel
|
| 6 |
Aim and Scope
|
|
|
|
138 |
S2 |
p. iii
|
artikel
|
| 7 |
Amplification of SNRPE promotes tumor proliferation and invasion in triple-negative breast cancer by activating mTOR signaling
|
Xie, G.
|
|
|
138 |
S2 |
p. S31-S32
|
artikel
|
| 8 |
An advanced in silico drug discovery platform, 4HF Data Miner for identifying novel targets for tumors and tumor-stroma
|
Das, S.
|
|
|
138 |
S2 |
p. S27
|
artikel
|
| 9 |
An allosteric modulator of PRC2 methyltransferase activity inhibits renal cancer cell proliferation
|
Gerona-Navarro, G.
|
|
|
138 |
S2 |
p. S23-S24
|
artikel
|
| 10 |
Analysis of the cystine/glutamate antiporter xCT (SLC7A11) as a biomarker in several tumor types using immunohistochemistry
|
Rojas, A.
|
|
|
138 |
S2 |
p. S27
|
artikel
|
| 11 |
Annona senegalensis extract demonstrates anticancer properties in N-diethylnitrosamine induced hepatocellular carcinoma in male wistar rats
|
Yakubu, O.
|
|
|
138 |
S2 |
p. S26
|
artikel
|
| 12 |
A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small cell lung cancer
|
Shen, Y.
|
|
|
138 |
S2 |
p. S45
|
artikel
|
| 13 |
Antibody blockade resets Chi3L1-induced glioma stem cell phenotypic transitions and reduces glioblastoma tumor burden
|
Guetta-Terrier, C.
|
|
|
138 |
S2 |
p. S52
|
artikel
|
| 14 |
Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma
|
Burrows, F.
|
|
|
138 |
S2 |
p. S43-S44
|
artikel
|
| 15 |
A phase Ib/II trial of high dose ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) with digital spatial profiling (DSP) in patients (pts) with metastatic pancreatic cancer (MPC)
|
Von Hoff, D.D.
|
|
|
138 |
S2 |
p. S55
|
artikel
|
| 16 |
A phase I/II study of JX-594 oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer
|
Monge, C.
|
|
|
138 |
S2 |
p. S57-S58
|
artikel
|
| 17 |
A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)
|
Lee, V.
|
|
|
138 |
S2 |
p. S12
|
artikel
|
| 18 |
A pivotal study in human prostate cancer tissues and cell lines to measure the expression levels of eukaryotic Elongation Factor 1A proteins and the effect of a nucleic acid-based GT75 aptamer
|
Scaggiante, B.
|
|
|
138 |
S2 |
p. S49
|
artikel
|
| 19 |
Arcagen: Molecular profiling of rare cancer patients – analysis of the pilot study (87 patients)
|
Morfouace, M.
|
|
|
138 |
S2 |
p. S32
|
artikel
|
| 20 |
Assessing the impact of cGAS-STING pathway activation on adoptive cell therapy using a patient-derived 3D ex vivo tumor organoid model
|
Pabon, M.
|
|
|
138 |
S2 |
p. S59
|
artikel
|
| 21 |
Author index
|
|
|
|
138 |
S2 |
p. S63-S70
|
artikel
|
| 22 |
Benchmarking syngeneic tumor models to explore immunopathogenesis and anti-PD1 mechanism of action
|
An, A.X.
|
|
|
138 |
S2 |
p. S59-S60
|
artikel
|
| 23 |
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients
|
Innocenti, F.
|
|
|
138 |
S2 |
p. S9-S10
|
artikel
|
| 24 |
CD8+ T tumour-infiltrating lymphocytes lacking CD5 cell surface expression exhibited increased levels of activation and exhaustion
|
Alotaibi, F.
|
|
|
138 |
S2 |
p. S60
|
artikel
|
| 25 |
CHD-loss promotes tumor heterogeneity, lineage plasticity and resistance to AR targeted therapy resistance
|
Mu, P.
|
|
|
138 |
S2 |
p. S22-S23
|
artikel
|
| 26 |
Chitinase-like proteins as candidate markers for tamoxifen responsiveness
|
Babyshkina, N.
|
|
|
138 |
S2 |
p. S41-S42
|
artikel
|
| 27 |
Circulating Tumor DNA Dynamics Predict Outcomes of Systemic Therapy in Patients with Advanced Cancers
|
Gouda, M.
|
|
|
138 |
S2 |
p. S3
|
artikel
|
| 28 |
Circulating tumour DNA analysis using three next generation sequencing approaches in a phase 1b trial of ER positive metastatic breast cancer
|
Masina, R.
|
|
|
138 |
S2 |
p. S19
|
artikel
|
| 29 |
Clinical pharmacokinetics of adavosertib in the presence or absence of PD-L1 inhibitor durvalumab in patients with refractory solid tumors
|
Miah, M.K.
|
|
|
138 |
S2 |
p. S45
|
artikel
|
| 30 |
Clinical significance of c-MYC/EZH-2 expression and Merlin loss
|
Arslan, A.M.
|
|
|
138 |
S2 |
p. S42
|
artikel
|
| 31 |
Clinical usefulness of tumor mutational burden (TMB) assessed by NGS in solid tumors
|
Kim, H.
|
|
|
138 |
S2 |
p. S31
|
artikel
|
| 32 |
c-Met activation leads to the establishment of a TGFβ-receptor regulatory network required for bladder cancer invasion
|
Eichhorn, P.
|
|
|
138 |
S2 |
p. S41
|
artikel
|
| 33 |
Combination PI3K and NOS targeted therapy for metaplastic breast cancer
|
Reddy, T.
|
|
|
138 |
S2 |
p. S49-S50
|
artikel
|
| 34 |
Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models
|
Smyth, T.
|
|
|
138 |
S2 |
p. S44-S45
|
artikel
|
| 35 |
Combined SHP2 and MEK inhibition is effective in models of NF1-deficient malignant peripheral nerve sheath tumors
|
Wang, J.
|
|
|
138 |
S2 |
p. S24-S25
|
artikel
|
| 36 |
Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC)
|
Lin, C.C.
|
|
|
138 |
S2 |
p. S12-S13
|
artikel
|
| 37 |
Correlation of molecular profiles with response to targeted drugs in pancreatic cancer models
|
Behrens, D.
|
|
|
138 |
S2 |
p. S58-S59
|
artikel
|
| 38 |
CX-2043, an EpCAM-targeting probody drug conjugate, demonstrates anti-tumor activity with a favorable safety profile in preclinical models
|
Liu, B.
|
|
|
138 |
S2 |
p. S15
|
artikel
|
| 39 |
Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models
|
Mcsheehy, P.
|
|
|
138 |
S2 |
p. S25-S26
|
artikel
|
| 40 |
Development of casein kinase 2 related oral cancer prevention targets by genomic database analysis
|
Koenigsberg, C.
|
|
|
138 |
S2 |
p. S49
|
artikel
|
| 41 |
Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers
|
Cadzow, L.
|
|
|
138 |
S2 |
p. S52
|
artikel
|
| 42 |
Development of metastatic tumor-targeting NIR persistent luminescence nanomaterials to treatment for lung cancer
|
Chan, M.H.
|
|
|
138 |
S2 |
p. S34-S35
|
artikel
|
| 43 |
Devimistat induces reprogramming of glycolytic metabolism to augment its anticancer potency in head and neck cancer
|
He, L.
|
|
|
138 |
S2 |
p. S34
|
artikel
|
| 44 |
Discovery and characterization of novel, potent, and selective hypoxiainducible factor (HIF)-2α inhibitors
|
Lawson, K.
|
|
|
138 |
S2 |
p. S16
|
artikel
|
| 45 |
Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors for cancer therapy
|
Miles, D.
|
|
|
138 |
S2 |
p. S38-S39
|
artikel
|
| 46 |
Discovery of Covalently-bound, First-in-Class Allosteric Inhibitor of PRMT5
|
McKinney, D.
|
|
|
138 |
S2 |
p. S1
|
artikel
|
| 47 |
Discovery proteomics detects expression trends associated with resistance to the most commonly used chemotherapies in esophageal adenocarcinoma
|
Mittal, S.
|
|
|
138 |
S2 |
p. S40
|
artikel
|
| 48 |
Disrupting cancer dynamics by a novel pleiotropic benzopyrane derivative
|
Altel, T.
|
|
|
138 |
S2 |
p. S38
|
artikel
|
| 49 |
Dissecting the landscape of CAF-mediated drug resistance mechanisms in ALK-rearranged NSCLC
|
Hu, Q.
|
|
|
138 |
S2 |
p. S48
|
artikel
|
| 50 |
Dissection of cancer therapy combinations in RTK driven tumors using zotatifin (eFT226), a potent and selective eIF4A inhibitor
|
Gerson-Gurwitz, A.
|
|
|
138 |
S2 |
p. S56
|
artikel
|
| 51 |
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
|
Poulikakos, P.
|
|
|
138 |
S2 |
p. S5
|
artikel
|
| 52 |
DNA methyltransferases drive gastric cancer growth and present a therapy target for gastric cancer
|
Huber, A.
|
|
|
138 |
S2 |
p. S43
|
artikel
|
| 53 |
Dose derivation of oral anticancer agents: Tolerability in late phase registration trials
|
McCabe, C.
|
|
|
138 |
S2 |
p. S51
|
artikel
|
| 54 |
DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models
|
Yamato, M.
|
|
|
138 |
S2 |
p. S14-S15
|
artikel
|
| 55 |
Dysregulated binding of Sp1 at double strand breaks increases cell sensitivity to PARP inhibition
|
Swift, M.
|
|
|
138 |
S2 |
p. S37
|
artikel
|
| 56 |
Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors
|
Papadopoulos, K.
|
|
|
138 |
S2 |
p. S50
|
artikel
|
| 57 |
Editorial Board
|
|
|
|
138 |
S2 |
p. ii
|
artikel
|
| 58 |
Emergence of novel long-acting mono- and bi-specific IL-2/IL-13 superkines as potent immune modulators
|
Merchant, F.
|
|
|
138 |
S2 |
p. S57
|
artikel
|
| 59 |
Engineered hydrogels to elucidate contributions of matrix mechanics to esophageal adenocarcinoma and identify matrix-activated therapeutic targets
|
Cruz-Acuña, R.
|
|
|
138 |
S2 |
p. S46
|
artikel
|
| 60 |
Enhanced tumor suppression by conditionally replicating adenovirus in multidrug-resistant human ovarian carcinoma
|
Ali, S.
|
|
|
138 |
S2 |
p. S48
|
artikel
|
| 61 |
Epidermal growth factor receptor influences the antigen presentation pathway in pancreatic cancer
|
Knoche, S.
|
|
|
138 |
S2 |
p. S60-S61
|
artikel
|
| 62 |
Epigenetic regulation of epithelial-to-mesenchymal transition as a captain of journey of cancer from lung to brain
|
Lee, Y.M.
|
|
|
138 |
S2 |
p. S43
|
artikel
|
| 63 |
Evaluation of [1,2]oxazolo[5,4-e]isoindoles in lymphoma cells
|
Barreca, M.
|
|
|
138 |
S2 |
p. S35-S36
|
artikel
|
| 64 |
Evaluation of surufatinib, an orally available VEGFR, FGFR1 and CSF-1R inhibitor, in combination with immune checkpoint blockade or chemotherapy in preclinical tumor models
|
Cheng, M.
|
|
|
138 |
S2 |
p. S25
|
artikel
|
| 65 |
Extended 8b inhibition of CDK 6 inhibits TWIST 1 expression and induces therapeutic senescence in KRASG13D mutant colon cancer
|
Qayum, A.
|
|
|
138 |
S2 |
p. S39
|
artikel
|
| 66 |
First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
|
Hong, D.
|
|
|
138 |
S2 |
p. S1
|
artikel
|
| 67 |
Fostriecin potentiates genome instability and anti-tumor immunity in ovarian cancer
|
Raja, R.
|
|
|
138 |
S2 |
p. S61
|
artikel
|
| 68 |
Functional genomics screens to identify genes involved in tolerance of tumour microenvironment stress
|
Lee, T.W.
|
|
|
138 |
S2 |
p. S30
|
artikel
|
| 69 |
Gemcitabine stimulates HLA class I expression in pancreatic cancer cells
|
Larson, A.
|
|
|
138 |
S2 |
p. S34
|
artikel
|
| 70 |
Genetically characterizing spontaneously-occurring cancer in canines to serve as a model for human studies
|
Lewis, B.
|
|
|
138 |
S2 |
p. S26-S27
|
artikel
|
| 71 |
Genome-scale genetic screening identifies PRMT1 as a critical vulnerability in castration-resistant prostate cancer
|
Tang, S.
|
|
|
138 |
S2 |
p. S7
|
artikel
|
| 72 |
GITR agonist sensitizes MC38/OVA tumor to CTLA4 treatment by attenuating Tregs in GITR HuGEMM
|
He, D.X.
|
|
|
138 |
S2 |
p. S15
|
artikel
|
| 73 |
Global chromatin landscape identifies bladder cancer metastatic progression
|
Varticovski, L.
|
|
|
138 |
S2 |
p. S30
|
artikel
|
| 74 |
Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAFV600E-mutated metastatic melanoma
|
Obrador, E.
|
|
|
138 |
S2 |
p. S41
|
artikel
|
| 75 |
HER2-XPAT, a novel protease-activatable pro-drug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)
|
Cattaruza, F.
|
|
|
138 |
S2 |
p. S10
|
artikel
|
| 76 |
High-Resolution Limited Proteolysis (HR-LIP): A novel approach for target validation and lead compound optimization
|
Feng, Y.
|
|
|
138 |
S2 |
p. S39
|
artikel
|
| 77 |
High-throughput small molecule screens reveal therapeutic opportunities against TFE3-fusion renal cell carcinoma
|
Lang, M.
|
|
|
138 |
S2 |
p. S17
|
artikel
|
| 78 |
hTERT and IGFIR protein expression as possible biomarkers and molecular targets in cervical cancer
|
Moreno-Acosta, P.
|
|
|
138 |
S2 |
p. S46
|
artikel
|
| 79 |
Hypoxia-activated prodrugs of DNA-dependent protein kinase as radiosensitisers
|
Hay, M.
|
|
|
138 |
S2 |
p. S13-S14
|
artikel
|
| 80 |
Identification of novel tumor suppressors for pancreatic cancer initiation and progression from normal human pancreatic acinar cells
|
Xu, Y.
|
|
|
138 |
S2 |
p. S29-S30
|
artikel
|
| 81 |
Identification of physiologically relevant EWS-FLI1 target genes in Ewing sarcoma via CRISPRa screening
|
Saratov, V.
|
|
|
138 |
S2 |
p. S24
|
artikel
|
| 82 |
Identification of potent small molecule allosteric inhibitors of SHP2
|
Hearn, K.
|
|
|
138 |
S2 |
p. S44
|
artikel
|
| 83 |
Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy
|
Strauss, J.
|
|
|
138 |
S2 |
p. S10
|
artikel
|
| 84 |
Inhibiting eIF4A in liposarcoma to identify key regulators using ribosome profiling
|
Mohan, P.
|
|
|
138 |
S2 |
p. S29
|
artikel
|
| 85 |
Inhibition of farnesyl transferase by tipifarnib leads to cell growth inhibition in HRAS-mutated human rhabdomyosarcoma
|
Obasaju, P.
|
|
|
138 |
S2 |
p. S46
|
artikel
|
| 86 |
Inhibition of 4NQO-induced oral squamous cell carcinoma progression by novel TGF-β inhibitors and PD-L1 antibodies
|
Ludwig, N.
|
|
|
138 |
S2 |
p. S19-S20
|
artikel
|
| 87 |
Inhibition of serum response factor as a new strategy to overcome resistance to enzalutamide in prostate cancer
|
Watson, W.
|
|
|
138 |
S2 |
p. S49
|
artikel
|
| 88 |
Initial results from a phase 1 trial of OKI-179, an oral Class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors
|
Diamond, J.
|
|
|
138 |
S2 |
p. S12
|
artikel
|
| 89 |
Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor
|
Janku, F.
|
|
|
138 |
S2 |
p. S2-S3
|
artikel
|
| 90 |
Interleukin 33: A new target against gastrointestinal cancer?
|
Eissmann, M.
|
|
|
138 |
S2 |
p. S60
|
artikel
|
| 91 |
Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
|
Bendell, J.
|
|
|
138 |
S2 |
p. S8-S9
|
artikel
|
| 92 |
Investigating synergy between WEE1 and PARP inhibitors in BRCA2 mutant and corrected cells
|
Smith, H.
|
|
|
138 |
S2 |
p. S36-S37
|
artikel
|
| 93 |
‘In vitro clinical trials’ platform for drug testing in patient-derived ex vivo 3D cultured human tumor tissues
|
Beztsinna, N.
|
|
|
138 |
S2 |
p. S59
|
artikel
|
| 94 |
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
|
Jänne, P.A.
|
|
|
138 |
S2 |
p. S1-S2
|
artikel
|
| 95 |
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
|
Johnson, M.L.
|
|
|
138 |
S2 |
p. S2
|
artikel
|
| 96 |
LiP-Quant, an automated chemoproteomic approach to identify drug targets in complex proteomes
|
Feng, Y.
|
|
|
138 |
S2 |
p. S54-S55
|
artikel
|
| 97 |
LncRNA H19/miR-486-5p/miR-17-5p: A novel immunoregulatory loop regulating TNBC cellular recognition by cytotoxic T lymphocytes and natural killer cells
|
Elkhouly, A.
|
|
|
138 |
S2 |
p. S56-S57
|
artikel
|
| 98 |
Long noncoding RNA functions as a direct transcriptional target of p73 and plays a critical role in suppression of cancer cell migration, invasion and metastasis via sponging of miR-1273g-3p
|
Uboveja, A.
|
|
|
138 |
S2 |
p. S30
|
artikel
|
| 99 |
Marine bioprospecting: Investigating new bioactive compounds with antineoplastic potential in glioblastoma
|
Silva, I.V. Gomes E
|
|
|
138 |
S2 |
p. S56
|
artikel
|
| 100 |
MatchMiner: Computational matching of cancer patients to precision medicine clinical trials
|
Mazor, T.
|
|
|
138 |
S2 |
p. S18
|
artikel
|
| 101 |
MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit.
|
Sampson, J.
|
|
|
138 |
S2 |
p. S6
|
artikel
|
| 102 |
Mechanism based signatures of TGFβ competency and DNA repair predict response to genotoxic therapies across cancer types
|
Barcellos-Hoff, M.
|
|
|
138 |
S2 |
p. S14
|
artikel
|
| 103 |
Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment
|
Sampaio, C.
|
|
|
138 |
S2 |
p. S23
|
artikel
|
| 104 |
Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
|
Gounder, M.M.
|
|
|
138 |
S2 |
p. S3-S4
|
artikel
|
| 105 |
miR-149-3p inhibits the GSC phenotype cells and re-sensitizes therapy-resistant GBM cells
|
Lopez-Bertoni, H.
|
|
|
138 |
S2 |
p. S33
|
artikel
|
| 106 |
Molecular and genetic determinants of dysfunctional wild type TP53 in glioblastoma
|
Zhao, Y.
|
|
|
138 |
S2 |
p. S27-S28
|
artikel
|
| 107 |
Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer reveals unique features that may inspire new sequential therapies in nonresponders
|
Marandino, L.
|
|
|
138 |
S2 |
p. S21
|
artikel
|
| 108 |
Multi-omics approaches to clarify adaptive mechanisms of cancer cells to antiproliferative effects by chromosomal instability
|
Morita, T.Y.
|
|
|
138 |
S2 |
p. S31
|
artikel
|
| 109 |
Multiple myeloma cells inhibit adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes
|
Reagan, M.
|
|
|
138 |
S2 |
p. S28
|
artikel
|
| 110 |
Mutations and copy number alterations in diffuse gliomas are shaped by different mechanisms
|
Ozduman, K.
|
|
|
138 |
S2 |
p. S32-S33
|
artikel
|
| 111 |
New antibody therapeutics targeting connexin hemichannels in treatment of osteosarcoma and breast cancer bone metastasis
|
Jiang, J.
|
|
|
138 |
S2 |
p. S54
|
artikel
|
| 112 |
NLS designed algorithm to develop peptides with a net-neutral charge as potential next-generation vectors for drug delivery to the nucleus
|
Rioux-Chevalier, A.
|
|
|
138 |
S2 |
p. S25
|
artikel
|
| 113 |
OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors
|
Hodges-Gallagher, L.
|
|
|
138 |
S2 |
p. S55
|
artikel
|
| 114 |
Optimal therapeutic positioning of a selective bi-steric inhibitor of MTORC1 in genetically defined cancers
|
Jiang, J.
|
|
|
138 |
S2 |
p. S53
|
artikel
|
| 115 |
ORIC-101 overcomes GR-driven resistance to AR degradation in castration-resistant prostate cancer models
|
Zhou, H.
|
|
|
138 |
S2 |
p. S22
|
artikel
|
| 116 |
PDK1 inhibitor SNS-510 shows synergy with targeted cancer therapies in solid tumor and hematologic cancer models
|
Taverna, P.
|
|
|
138 |
S2 |
p. S45
|
artikel
|
| 117 |
Peer Review Policy for the European Journal of Cancer (EJC)
|
|
|
|
138 |
S2 |
p. iv
|
artikel
|
| 118 |
Phase IIa/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus Pembrolizumab in patients with head and neck cancer (HNSCC) who have failed platinum or a platinum-containing regimen
|
Osada, A.
|
|
|
138 |
S2 |
p. S35
|
artikel
|
| 119 |
Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
|
Do, K.T.
|
|
|
138 |
S2 |
p. S7
|
artikel
|
| 120 |
Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor
|
Kizilbash, S.H.
|
|
|
138 |
S2 |
p. S11-S12
|
artikel
|
| 121 |
Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells
|
Nagashima, H.
|
|
|
138 |
S2 |
p. S14
|
artikel
|
| 122 |
Positive association between macrophage infiltration and PD-L1 expression in the tumor microenvironment
|
Cumberbatch, M.
|
|
|
138 |
S2 |
p. S62
|
artikel
|
| 123 |
Potent anti-tumor activity of AUR102, a selective covalent inhibitor of CDK7
|
Satyam, L.K.
|
|
|
138 |
S2 |
p. S47
|
artikel
|
| 124 |
Potential lung cancer therapy using plant derived cholesterol structural analogs
|
Perez, D.
|
|
|
138 |
S2 |
p. S42
|
artikel
|
| 125 |
Potential use of the PARP inhibitor rucaparib to enhance cervical cancer treatment
|
Saha, S.
|
|
|
138 |
S2 |
p. S37
|
artikel
|
| 126 |
Preclinical therapeutic synergy of MEK1/2 and IGF1R inhibition in RAS-driven rhabdomyosarcoma
|
Yohe, M.
|
|
|
138 |
S2 |
p. S48
|
artikel
|
| 127 |
Preferences of US adults with Ph+ALL for first-line treatment with TKI-chemotherapy combinations: A discrete choice experiment
|
Ashaye, A.
|
|
|
138 |
S2 |
p. S51-S52
|
artikel
|
| 128 |
Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors
|
Janku, F.
|
|
|
138 |
S2 |
p. S11
|
artikel
|
| 129 |
Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924
|
Andric, Z.
|
|
|
138 |
S2 |
p. S5
|
artikel
|
| 130 |
Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC)
|
Houghton, P.J.
|
|
|
138 |
S2 |
p. S18
|
artikel
|
| 131 |
Proteomics reveal extensive translatome reprogramming and biomarkers of rocaglate toxicity and resistance in cancer
|
Ho, J.J.D.
|
|
|
138 |
S2 |
p. S28-S29
|
artikel
|
| 132 |
PT-112, a first-in-class pyrophosphate-platinum conjugate, selectively targets highly glycolytic tumor cells
|
Soler, R.
|
|
|
138 |
S2 |
p. S53-S54
|
artikel
|
| 133 |
Quantification of myeloid cell repolarization and their interplay with the tumor in 3D with image-based analysis
|
Goverse, G.
|
|
|
138 |
S2 |
p. S57
|
artikel
|
| 134 |
RAS orchestrates an increase of interstitial adenosine in lung adenocarcinoma to promote immune evasion
|
de Carné Trécesson, S.
|
|
|
138 |
S2 |
p. S20-S21
|
artikel
|
| 135 |
Regorafenib targets YAP1 to inhibit epithelial-mesenchymal transition and cancer metastasis of cholangiocarcinoma
|
Chang, Y.C.
|
|
|
138 |
S2 |
p. S47-S48
|
artikel
|
| 136 |
Regulation of MDSCs in the urothelial carcinoma of bladder: Relevant role of YAP1
|
Sadhukhan, P.
|
|
|
138 |
S2 |
p. S61-S62
|
artikel
|
| 137 |
Repotrectinib increases KRAS-G12C inhibitor effectiveness via simultaneous inhibition of SRC, FAK, and JAK2
|
Murray, B.
|
|
|
138 |
S2 |
p. S39-S40
|
artikel
|
| 138 |
Restricted STAT3 inhibition among tumour infiltrating immune cells restricts colorectal tumour growth
|
Alorro, M.
|
|
|
138 |
S2 |
p. S61
|
artikel
|
| 139 |
Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors
|
Macchini, M.
|
|
|
138 |
S2 |
p. S5-S6
|
artikel
|
| 140 |
Role of AKT3 in the intrinsic radioresistance of lung adenocarcinoma
|
Chauhan, A.
|
|
|
138 |
S2 |
p. S36
|
artikel
|
| 141 |
Role of miR-21 in chemotherapeutic drug resistance of oral squamous cell carcinoma
|
Chatterjee, N.
|
|
|
138 |
S2 |
p. S41
|
artikel
|
| 142 |
SCLC subtype-enriched biomarkers define positioning of Aurora B inhibitor combination with venetoclax
|
Della Corte, C.
|
|
|
138 |
S2 |
p. S47
|
artikel
|
| 143 |
Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models
|
Spriano, F.
|
|
|
138 |
S2 |
p. S17
|
artikel
|
| 144 |
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
|
Arribas, A.
|
|
|
138 |
S2 |
p. S40
|
artikel
|
| 145 |
Small molecule compound induces cell cycle arrest and subsequent apoptosis in an in-vitro model of triple negative breast cancer
|
Okpechi, S.
|
|
|
138 |
S2 |
p. S29
|
artikel
|
| 146 |
Small molecule PTP4A3 phosphatase inhibitors targeting acute myeloid leukemia
|
Lazo, J.
|
|
|
138 |
S2 |
p. S55-S56
|
artikel
|
| 147 |
SOX2-mediated 5hmC dysregulation in GBM Stem Cells
|
Lopez-Bertoni, H.
|
|
|
138 |
S2 |
p. S33-S34
|
artikel
|
| 148 |
Stratification method based on RAS pathway oncogenic activity predicts outcome in lung adenocarcinoma
|
East, P.
|
|
|
138 |
S2 |
p. S18
|
artikel
|
| 149 |
Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers with chromosome 18q or 16q deletion
|
Neggers, J.
|
|
|
138 |
S2 |
p. S8
|
artikel
|
| 150 |
Table of Contents
|
|
|
|
138 |
S2 |
p. v-vi
|
artikel
|
| 151 |
Targeting a KRAS neoantigen peptide vaccine to DNGR-1+ dendritic cells
|
Ambler, R.
|
|
|
138 |
S2 |
p. S10
|
artikel
|
| 152 |
Targeting BRAF WT metastatic melanomas: Identifying ERBB4 mutant alleles as biomarkers for novel combinatorial treatment strategies
|
Lucas, L.
|
|
|
138 |
S2 |
p. S32
|
artikel
|
| 153 |
Targeting immune tolerance and stromal fibrosis with an LXR agonist in a conditional transgenic model of mammary fibrosis
|
Glazer, R.
|
|
|
138 |
S2 |
p. S20
|
artikel
|
| 154 |
Targeting oncogenic signalling pathways to modulate the lung cancer immune microenvironment
|
Van Maldegem, F.
|
|
|
138 |
S2 |
p. S60
|
artikel
|
| 155 |
TAS1553, a novel class of RNR inhibitor, has robust antitumor activity in murine syngeneic tumor models as a single agent and in combination with anti-PD-1 checkpoint inhibitor
|
Fukushima, H.
|
|
|
138 |
S2 |
p. S58
|
artikel
|
| 156 |
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation
|
Scagliotti, A.
|
|
|
138 |
S2 |
p. S26
|
artikel
|
| 157 |
The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
|
Odintsov, I.
|
|
|
138 |
S2 |
p. S15-S16
|
artikel
|
| 158 |
The antitumor role of glatiramer acetate and fingolimod in neural tumor cell lines
|
Doello, K.
|
|
|
138 |
S2 |
p. S54
|
artikel
|
| 159 |
The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models
|
Munck, J.
|
|
|
138 |
S2 |
p. S53
|
artikel
|
| 160 |
The functional anatomy of chimeric antigen receptors in acute T cell responses to antigen
|
Xu, H.
|
|
|
138 |
S2 |
p. S33
|
artikel
|
| 161 |
The integrated stress response exposes a therapeutic vulnerability in KRAS driven lung cancer
|
Ghaddar, N.
|
|
|
138 |
S2 |
p. S23
|
artikel
|
| 162 |
The marine natural product HB-395 selectively induces apoptosis in MDA-MB-231 triple negative breast cancer cell spheroids
|
Guzman, E.
|
|
|
138 |
S2 |
p. S29
|
artikel
|
| 163 |
The non-peptidomimetic cIAP1/2 and XIAP antagonist ASTX660 promotes an anti-tumour immune response in T-cell lymphoma
|
Ferrari, N.
|
|
|
138 |
S2 |
p. S28
|
artikel
|
| 164 |
The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer
|
Hong, N.H.
|
|
|
138 |
S2 |
p. S51
|
artikel
|
| 165 |
Theranostic 64Cu-DOTHA2-PSMA for metastatic prostate cancer treatment, a preclinical study
|
Milot, M.C.
|
|
|
138 |
S2 |
p. S24
|
artikel
|
| 166 |
The role of enhancer RNAs in glioblastoma multiforme
|
Akobundu, B.
|
|
|
138 |
S2 |
p. S42-S43
|
artikel
|
| 167 |
The synergistic action of isolated sesquiterpene with cisplatin against non-small cell lung cancer cells
|
Ahmed, A.
|
|
|
138 |
S2 |
p. S34
|
artikel
|
| 168 |
Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody
|
Blø, M.
|
|
|
138 |
S2 |
p. S44
|
artikel
|
| 169 |
Tinagl1 gene therapy for tumor-wide remodeling of triple negative breast cancer
|
Musetti, S.
|
|
|
138 |
S2 |
p. S37-S38
|
artikel
|
| 170 |
Title Page
|
|
|
|
138 |
S2 |
p. i
|
artikel
|
| 171 |
TPX-0005 (Repotrectinib), a next-generation ALK/ROS1/NTRK1–3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models
|
O’donohue, T.
|
|
|
138 |
S2 |
p. S16-S17
|
artikel
|
| 172 |
Transcriptome comparison among patients, PDX, PDO, PDXO, PDXC and cell lines
|
Mao, B.
|
|
|
138 |
S2 |
p. S31
|
artikel
|
| 173 |
Transition state analogue of MTAP extends lifespan of APCMin/+ mice
|
Firestone, R.
|
|
|
138 |
S2 |
p. S39
|
artikel
|
| 174 |
Tumor cell membrane-based peptide delivery system targeting to tumor microenvironment for cancer immunotherapy and diagnosis
|
Zhu, Y.
|
|
|
138 |
S2 |
p. S37
|
artikel
|
| 175 |
Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen
|
Gerritse, S.
|
|
|
138 |
S2 |
p. S19
|
artikel
|
| 176 |
USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors
|
Sullivan, P.
|
|
|
138 |
S2 |
p. S7-S8
|
artikel
|
| 177 |
Vertical pathway inhibition with a SOS1::KRAS inhibitor enhances the efficacy of KRAS G12C inhibitors, delays feedback resistance and demonstrates durable response
|
Savarese, F.
|
|
|
138 |
S2 |
p. S22
|
artikel
|
| 178 |
Visualization and quantification of anti-tumor immune responses in 3D cultures
|
Goverse, G.
|
|
|
138 |
S2 |
p. S62
|
artikel
|
| 179 |
XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile
|
Hsu, J.
|
|
|
138 |
S2 |
p. S16
|
artikel
|
Tijdschrift beschrijving